News
26.04.2018 | Company News
Neurimmune appoints Fabian Buller as Chief Business Officer09.11.2017 | Press Release
Neurimmune Announces Collaboration with Ono Pharmaceutical in Neurodegenerative Diseases Field24.10.2017 | Company News
Neurimmune Raises $150 Million to Finance its Growth Strategy19.02.2017 | Company News
BIIB076 Moves into Phase 1 for Alzheimer's Disease26.01.2017 | Company News
Neurimmune's joint research project with University of Zurich awarded Pfizer Research Prize 201731.08.2016 | Press Release
Early Results Show Aducanumab Removes Amyloid Plaques in Patients with Alzheimer's Disease01.06.2016 | Company News
Aducanumab accepted into EMA's PRIME Program